Skip to main content
Back
Watch Compare

SAB Biotherapeutics, Inc.

Data quality: 100%
Also listed as SABSW Nasdaq
SABS
Nasdaq Manufacturing Chemicals
$3.83
▲ $0.10 (2.55%)
Mkt Cap: 268.80 M
Price
$3.83
Mkt Cap
268.80 M
Day Range
$3.65 — $3.86
52-Week Range
$1.14 — $6.60
Volume
181,875
Open $3.71
50D / 200D Avg
$4.01
4.61% below
50D / 200D Avg
$3.12
22.55% above

Quick Summary

Key Takeaways

ROE of 14.99% — decent returns on equity
Negative free cash flow of -45.71 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
14.99%
Above sector avg (-51.02%)
ROIC-50.96%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio10.50
Interest Coverage-203.41

Valuation

PE (TTM)
20.25
Above sector avg (-1.98)
P/B Ratio1.63
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E 20.3 -2.0
P/B 1.6 5.1
ROE % 15.0 -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) 13.27 M
ROE 14.99% ROA 12.43%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45.71 M
ROIC -50.96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.50
Interest Coverage -203.41 Asset Turnover 0.00
Working Capital 102.48 M Tangible Book Value 165.07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 20.25 Forward P/E N/A
P/B Ratio 1.63 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -17.00%
Market Cap 268.80 M Enterprise Value 239.38 M
Per Share
EPS (Diluted TTM) -0.79 Revenue / Share 0.00
FCF / Share -0.65 OCF / Share -0.64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -344.35%
SBC-Adj. FCF -48.80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Revenue 0.0 1.32 M 2.24 M 23.90 M —
Net Income 13.27 M -34.11 M -42.19 M -18.74 M -8,996.0
EPS (Diluted) -0.79 -3.68 -7.64 — —
Gross Profit — — — — —
Operating Income -48.95 M -42.91 M -38.08 M -28.92 M —
EBITDA — — — — —
R&D Expenses 34.35 M 30.25 M 16.52 M 36.44 M —
SG&A Expenses — — — — —
D&A 2.99 M 4.71 M 3.65 M 3.17 M —
Interest Expense 240,664.0 318,401.0 315,284.0 301,584.0 —
Income Tax 0.0 0.0 0.0 25,629.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 172.81 M 44.20 M 83.94 M 50.90 M 322,205.0
Total Liabilities 21.32 M 18.23 M 26.64 M 19.85 M —
Shareholders' Equity 151.49 M 25.97 M 57.30 M 31.06 M 16,004.0
Total Debt — — — — —
Cash & Equivalents 10.50 M 8.90 M 56.57 M 15.05 M —
Current Assets 101.05 M 23.79 M 58.91 M 22.10 M 87,094.0
Current Liabilities 10.68 M 7.98 M 10.81 M 14.99 M 306,201.0